Tesamorelin + Ipamorelin

Source-reported examples · not treatment recommendations

Amount

Inconsistent source table; no usable dose conversion provided

Frequency

Source describes daily administration

Cycle / observation period

Source describes 8–16 weeks

Route / research model

Subcutaneous

The page specifies 5 mg of each component, a 1:1 ratio, but its dose table uses a 2:1 ratio. One withdrawal from that blend cannot deliver those unequal component amounts. Its dosing table must not be used.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Supply calculation is withheld because the source dose ratio conflicts with the stated blend ratio.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.

• A 2007 randomized trial enrolled 412 people with HIV and abdominal fat accumulation. Over 26 weeks, CT-measured visceral fat decreased in the tesamorelin group and increased in the placebo group. The intervention did not include ipamorelin. ^[1]
• A randomized study in 50 people with HIV and abdominal fat accumulation found reductions in visceral and liver fat with tesamorelin over six months. It also reported an early fasting-glucose increase; the six-month glucose comparison was not significant. ^[2]
• Ipamorelin was studied in a placebo-controlled postoperative bowel-resection trial. The key time-to-tolerated-meal result was not statistically significant. That study did not evaluate visceral-fat reduction or the tesamorelin combination. ^[3]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 14 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original report
2. Original study
3. Original ipamorelin trial
4. PMC — The Safety and Efficacy of Growth Hormone SecretagoguesFurther reading · Listed in reference bibliography.
5. Endocrine Reviews — Growth Hormone SecretagoguesFurther reading · Listed in reference bibliography.
6. NCBI LiverTox — TesamorelinFurther reading · Listed in reference bibliography.
7. PubMed — Ipamorelin, the first selective growth hormone secretagogueFurther reading · Listed in reference bibliography.
8. FDA Egrifta (tesamorelin) LabelRegulatory / product information · Listed in reference bibliography.
9. CDC — Vaccine Administration: Subcutaneous InjectionGeneral guidance · Listed in reference bibliography.
10. European Journal of Endocrinology — Ipamorelin GH selectivityNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
11. PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelinFurther reading · Listed in reference bibliography.
12. JAMA — Tesamorelin for Abdominal Fat in HIVFurther reading · Listed in reference bibliography.
13. CDC — Vaccine Administration DuringGeneral guidance · Listed in reference bibliography.
14. NCBI Bookshelf — Best Practices for InjectionFurther reading · Listed in reference bibliography.
15. PMC — Subcutaneous Drug Injection ReviewFurther reading · Listed in reference bibliography.
16. Drugs — Tesamorelin: A ReviewNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.